1. Müllerová H., Shukla A., Hawkins A., Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014; 4 (12): e006171. https://doi.org/10.1136/bmjopen-2014-006171.
2. Johannesdottir S.A., Christiansen C.F., Johansen M.B. et al. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: A population-based Danish cohort study. J. Med. Econ. 2013; 16 (7): 897-906. https://doi.org/10.3111/13696998.2013.800525.
3. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Рос - сийское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмо - нология. 2014; (3): 15-54. https://doi.org/10.18093/0869-0189-2014-0-3-15-54.
4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2019 Re - port. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf [Accessed: November 11, 2018].
5. King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin. Transl. Med. 2015; 4: 26. https://doi.org/10.1186/s40169-015-0068-z.
6. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118-125. https://doi.org/10.1136/thoraxjnl-2015-207021.
7. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-963. https://doi.org/10.1136/thoraxjnl-2011-201518.
8. Miravitlles M., Soler-Cataluña J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur. Respir. J. 2013; 41 (6): 1252-1256. https://doi.org/10.1183/09031936.00118912.
9. Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014; 44 (6): 1697-1700.
10. Kolsum U., Damera G., Pham T.H. et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J. Allergy Clin. Immunol. 2017; 140 (4): 1181-1184e7. https://doi.org/10.1183/09031936.00162414.
11. Pavord I.D., Chanez P., Criner G.J. et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N. Engl. J. Med. 2017; 377: 1613-1629. https://doi.org/10.1056/NEJMoa1708208.
12. Ortega H.G., Yancey S.W., Mayer B. et al. Severe eosino - philic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir. Med. 2016; 4 (7): 549-556. https://doi.org/10.1016/S2213-2600(16)30031-5.
13. Alfageme I., Reyes N., Merino M. et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron. Respir. Dis. 2010; 7 (3): 135-145. https://doi.org/10.1177/1479972310368692.
14. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1138.
15. Soler-Cataluña J.J., Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: How much real, how much fictitious? COPD. 2010; 7 (4): 276-284. https://doi.org/10.3109/15412555.2010.496817.
16. Cosío B.G., Dacal D., de Llano L.P. Asthma-COPD overlap: identification and optimal treatment. Ther. Adv. Respir. Dis. 2018; 12: 1753466618805662. https://doi.org/10.1177/1753466618805662.
17. Невзорова В.А., Авдеев С.Н., Кондрашова Н.М. и др. Дискуссионные вопросы терапии хронической обструктивной болезни легких (материалы совета экспертов ДФО от 13.06.2018 г., Владивосток). Тихоокеанский медицинский журнал. 2019; 1 (75): 5-12.
18. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497-1504. https://doi.org/10.1164/rccm.200410-1414OC.
19. Овчаренко С.И., Лещенко И.В. Хроническая обструктивная болезнь легких: Руководство для практикующих врачей. Под ред. А.Г. Чучалина. М.: ГЭОТАРМедиа; 2016.
20. Singh D., Brooks J., Hagan G. et al. Superiority of ”triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63 (7): 592-598. https://doi.org/10.1136/thx.2007.087213.
21. Lee S.D., Xie C.M., Yunus F. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology. 2016; 21 (1): 119-127. https://doi.org/10.1111/resp.12646.
22. Usmani O.S., Singh D., Spinola M. et al. The prevalence of small airways disease in adult asthma: a systematic literature review. Respir. Med. 2016; 116: 19-27. https://doi.org/10.1016/j.rmed.2016.05.006.
23. Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Со - гласованные рекомендации по обоснованию выбора терапии бронхиальной астмы и хронической обструктивной болезни легких с учетом фенотипа заболевания и роли малых дыхательных путей. Атмосфера. Пульмонология и аллергология. 2013; (2): 15-26.
24. Yanai M., Sekizawa K., Ohrui T. et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J. Appl. Physiol. (1985). 1992; 72 (3): 1016-1023. https://doi.org/10.1152/jappl.1992.72.3.1016.
25. Burgel P.R. The role of small airways in obstructive airway diseases. Eur. Respir. Rev. 2011; 20 (119): 023-033. https://doi.org/10.1183/09059180.00010410.
26. Postma D.S., Brightling C., Baldi S. et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir. Med. 2019; 7 (5): 402-416. https://doi.org/10.1016/S2213-2600(19)30049-9.
27. Cottini M., Lombardi C., Micheletto C. Small airway dysfunction and bronchial asthma control: the state of the art. Asthma Res. Prac. 2015; 1: 13. https://doi.org/10.1186/s40733-015-0013-3.
28. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclo - methasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153-1162. https://doi.org/10.1016/j.rmed.2014.05.013.
29. Singh D., Corradi M., Spinola M. et al. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim. Care Respir. Med. 2016; 26: 16030. https://doi.org/10.1038/npjpcrm.2016.30.
30. Brusselle G., Pavord I.D., Landis S. et al. Blood eosinophil levels as a biomarker in COPD. Respir. Med. 2018; 138: 21-31. https://doi.org/10.1016/j.rmed.2018.03.016.
31. Nair P. Update on clinical inflammometry for the management of airway diseases. Can. Respir. J. 2013; 20: 602936. https://doi.org/10.1155/2013/602936.
32. Lipworth B.J., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3003-3009. https://doi.org/10.2147/copd.s177333.
33. Postma D.S., Roche N., Colice G. et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 1163-1186. https://doi.org/10.2147/COPD.S68289.
34. Crisafulli E., Pisi R., Aiello M. et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017; 93: 32-41. https://doi.org/10.1159/000452479.
35. Singh D., Nicolini G., Bindi E. et al. Extrafine Beclometha - sone/Formoterol Compared to Fluticasone/Salmeterol Com bination Therapy in COPD. BMC Pulm Med. 2014; 14: 43. https://doi.org/10.1186/1471-2466-14-43.
36. Sonnappa S., Martin R., Israel E. et al. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017; 15; 12 (6): e0178112. https://doi.org/10.1371/journal.pone.0178112.